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76 S. Vasoo et al.Introduction validated the detection of C. difficile toxin in stool speci-
Diagnostic testing for Clostridium difficile infection (CDI)
has undergone a paradigm shift in recent years. While most
clinical laboratories in Asia, Europe and the USA still utilize
rapid and inexpensive toxin A/B enzyme immunoassays
(EIAs), it is increasingly recognized that these tests have
poor sensitivity, ranging from 32% to 73%.1 Nucleic acid
amplification tests (NAATs) have emerged as highly sensi-
tive tests but costs and instrumentation pose challenges for
widespread implementation. EIAs using the C. difficile
common antigen, glutamate dehydrogenase (GDH Ag),
represent a cheaper and rapid alternative for detection of
C. difficile, with reported sensitivity of >90%,2,3 but have
to be used as part of an algorithm using a second confir-
matory test that detects toxin.4
Methods
The aim of our study was to evaluate a modified two-step
algorithm consisting of an initial rapid combined GDH
Ag/toxin EIA test [C. Diff Quik Chek Complete (CdQCC),
Techlab, Blacksburg, VA, USA] followed by RT-PCR for
indeterminate results in comparison to upfront RT-PCR and
our current methodology (Wampole Toxin A/B EIA, Techlab)
for the diagnosis of CDI in our institution. For RT-PCR, we
evaluated two assays that detect the tcdB gene (encoding
toxin B) of C. difficile: the Progastro Cd Assay (Gen-Probe
Prodesse, Waukesha, WI, USA) and the BD GeneOhm C. diff
Assay (BD Diagnostics, GeneOhm, San Diego, CA, USA). A
total of 192 stool samples (54 positive and 138 negative by
Wampole Toxin A/B EIA) from patients with suspected CDI
submitted to the Rush University Medical Center (RUMC)
clinical microbiology laboratory from January 2009 to March
2010 were included in the study. Specimens were stored at
4C and processed within 24 hours for the Wampole Toxin
A/B EIA. Testing with the other methodologies was carried
out on the same day if possible; if not, specimens were
frozen ate70C, and thawed once for testing. We previouslyTable 1 Distribution of results for four C. difficile assays
Total per category
(N Z 192)
Wampole
Toxin A/B EIA
C. Diff Quik Ch
Complete
GDH Ag Toxi
34 þ þ þ
1 e þ þ
4 e þ e
5 þ þ e
1 þ e þ
13 þ e e
15 e þ e
1a e e e
1b e þ e
1b þ e þ
1b e þ þ
115 e e e
a Specimen considered negative.
b Toxigenic stool cultures were positive for all three specimens.mens stored at e70 C (data not shown). All tests were
performed according to the manufacturers’ instructions by
trained personnel blinded to results from the other assays.
Specimens were considered positive for the CdQCC test
if both GDH Ag and toxin EIA were positive (Agþ/Toxþ),
negative if both GDH Ag and toxin EIA were negative (Age/
Toxe) and indeterminate if only either the GDH Ag or toxin
EIA was positive (Age/Toxþ or Agþ/Toxe). Overall, speci-
mens were considered true positives if both RT-PCR assays
were positive. Discrepant RT-PCR results were resolved
using toxigenic stool culture as previously described.5 The
performance characteristics were calculated using concor-
dant RT-PCR results or toxigenic stool culture as the gold
standard. The McNemar test was performed using SPSS
version 16.0. Values of p < 0.05 were considered signifi-
cant. This study was approved with exempt status by the
Institutional Review Board of RUMC.Results
A total of 192 stool isolates were tested, representing 173
unique patient encounters. Some 115 specimens were
negative by all four assays. Forty-eight specimens were
considered positive for toxin (true positives): 45 speci-
mens were positive by both RT-PCR assays and three
specimens were positive by the BD GeneOhm RT-PCR
assay alone and confirmed by toxigenic stool culture
(Table 1). The GDH Ag component of the CdQCC
successfully identified 46 of the 48 true positive speci-
mens (sensitivity 95.8%), while the toxin component alone
was positive for two CdQCC specimens (both positive by
RT-PCR/culture). Some 25 of 192 specimens (13%) were
Agþ/Toxe; 10/25 (40%) were positive by RT-PCR. The
sensitivity of the BD GeneOhm RT-PCR and Progastro Cd
RT-PCR tests were 100% and 93.8%, respectively (McNe-
mar test, p Z 0.25; Table 2). The average cost per test
was about US $13.60 (algorithm) versus US$26.00 (upfront
RT-PCR; Table 3).ek BD GeneOhm RT-PCR Progastro Cd RT-PCR
n A/B
þ þ
þ þ
þ þ
þ þ
þ þ
e e
e e
e Indeterminate
þ e
þ e
þ e
e e
Table 2 Test performance characteristics
Test Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Wampole Tox A/B EIA 85.4 (71.6e93.5) 90.9 (84.8e94.9) 75.9 (62.1e86.1) 94.9 (89.4e97.8)
C. Diff Quik Chek Complete GDH Ag component 95.8 (84.6e99.3) 89.6 (83.1e93.8) 75.4 (62.4e85.2) 98.4 (94.0e99.7)
C. Diff Quik Chek Complete Toxin component 79.2 (64.6e89.0) 100 (96.8e100) 100 (88.6e100) 93.5 (88.1e96.7)
Algorithm (C. diff Quik Chek Complete þ RT-PCR)
reflexed to BD GeneOhm RT-PCR for
discordant results
100 (90.8e100) 100 (96.8e100) 100 (90.8e100) 100 (96.8e100)
BD GeneOhm RT-PCR 100 (90.8e100) 100 (96.8e100) 100 (90.8e100) 100 (96.8e100)
Progastro Cd RT-PCRa 93.8 (81.8e98.4) 99.3 (95.6e100) 97.8 (87.0e99.9) 97.9 (93.6e99.5)
a One specimen that was indeterminate with Prograstro Cd RT-PCR coded as a false positive (all other assays were negative).
Data are presented as mean (95% confidence interval).
EIAZ enzyme immunoassay; GDH AgZ glutamate dehydrogenase antigen; NPVZ negative predictive value; PPVZ positive predictive
value.
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To improve the sensitivity and cost-effectiveness of CDI
diagnoses, a number of alternatives to EIA toxin tests have
been advocated, including an algorithm approach using
GDH Ag as an initial screen followed by confirmation of
toxin production using sensitive but laborious techniques
such as toxigenic culture or cytotoxin assay.4,6 There are
few data for a modified step-wise approach that involves
rapid and simultaneous detection of GDH Ag and C. difficile
toxin followed by RT-PCR. We found that a modified two-
step algorithm with the CdQCC led to accurate resolution
of 86% of specimens within 25 minutes. This is similar to
resolution rates of 92.6% and 88% reported by Swindells
et al. and Sharp et al., respectively.2,3 The GDH Agþ/Toxe
specimens (14% specimens) were easily resolved by RT-PCR,
which confirms that there is no need for up-front RT-PCR.
We found that the algorithm approach offers the bestTable 3 Comparison of testing algorithmsa
Test algorithm Estimated cost (US$)b
Per test Per 1000 tests
Wampole Toxin
A/B EIA alone
7.89 7890 (only 1 EIA)
14,462 (1 repeat EIA
initially negative spe
20,348 (2 repeat EIAs
initially negative spe
C. Diff QuikChek GDH
Ag/ToxinEIA reflexed
to GeneOhm RT-PCR
for discordant results
11.50 (QuikChek
alone)
Additional 26.95
for RT-PCR
13,663
(using 2 step algorith
BD GeneOhm
RT-PCR alone
26.95 26,950
Progastro Cd
RT-PCR alone
25.00 25,000
a Assuming 10% prevalence of CDI in specimens tested (based on re
b Cost based on list prices.
c Assuming 86% of tests can be initially resolved using the C. Diff Q
CI Z confidence interval.balance of speed, sensitivity and cost savings per test
(Table 3, Fig. 1).
Recent concerns regarding the sensitivity of GDH with
different ribotypes7 are probably because not all GDH Ag
assays are equivalent in their performance characteristics,
given that GDH seems to be highly conserved among C.
difficile ribotypes.8 Peterson et al. recently compared the
performance of two different GDH Ag assays to RT-PCR,
a stool cytotoxin assay and stool culture and found that
only the CdQCC (besides a single commercial RT-PCR assay)
had comparable sensitivity to broth-enriched toxigenic
C. difficile culture.9 Interestingly, culture failed to detect
approximately 6.8% of what was classified as true CDI in this
study,9 which underscores the challenge of finding a reli-
able gold-standard test for C. difficile.
A limitation of our study was that toxigenic culture was
not performed on all isolates; instead, a surrogate gold
standard concordance of two commercially available RT-PCRFalse positives/
1000 tests
False negatives/
1000 tests
Turnaround
time
(95% CI) (95% CI)
82 (46e137) 15 (6e28) 30 minutes,
batchedfor
cimens)
for
cimens)
m)c
0 (0e29) 0 (0e9) 25 minutes
(QuikChek)
real time,
random access
results
0 (0e29) 0 (0e9) 2 hours,
batched
6 (0e40) 6 (2e18) 3 hours,
batched
cent prevalence rates at RUMC from February to March 2010).
uikChek GDH Ag/Toxin EIA.
Figure 1. Modified two-step testing algorithm for Clos-
tridium difficile infection. CDI Z Clostridium difficile infec-
tion; EIA Z enzyme immunoassay; GDH Ag Z glutamate
dehydrogenase antigen; tcdB Z toxin B gene.
78 S. Vasoo et al.assays with toxigenic culture for discrepant RT-PCR assay
results was used. Therefore, the sensitivity estimated for
the algorithm and RT-PCR assays would be higher than ex-
pected. However, as the main aim of our study was to
compare the CdQCC and the modified two-step algorithm
with two commercially available RT-PCR assays for which the
performance characteristics have been well described in the
literature, we felt that this was a reasonable approach.
In summary, we found that a modified two-step algo-
rithm (CdQCC followed by RT-PCR for indeterminate
results) is a practical, rapid and cost-effective approach for
the diagnosis of CDI. This would especially be suitable for
small to medium-sized hospital laboratories for which
upfront molecular testing is prohibitive.
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